The level of urinary semaphorin3A is associated with disease activity in patients with minimal change nephrotic syndrome

Research output: Contribution to journalArticle

Abstract

Semaphorin3A is a secreted protein known to be involved in organogenesis, immune responses and cancer. In the kidney, semaphorin3A is expressed in the glomerular podocytes, distal tubules and collecting tubules, and believed to play a role in the regulation of the kidney development and function. We examined the serum and urinary semaphorin3A levels in 72 patients with renal disease and 5 healthy volunteers. The patients had been diagnosed with thin basement membrane disease (n=4), minimal change nephrotic syndrome (MCNS; n=22), IgA nephritis (n=21), membranous nephropathy (n=16) and focal segmental glomerular sclerosis (n=9). The level of urinary semaphorin3A in MCNS patients tended to be relatively high among all disease groups. We also investigated the urinary semaphorin3A level in 7 patients with MCNS from disease onset to remission during the drug therapy. MCNS patients in preremission states had higher urinary semaphorin3A levels than those in post-remission states receiving immunosuppressive therapies. These results suggested that the urinary semaphorin3A level correlates with the MCNS activity. Semaphorin3A has the potential as a biomarker for MCNS to clarify the reactivity for therapy and may be useful in examining other glomerular diseases with proteinuria as well.

Original languageEnglish
Pages (from-to)167-174
Number of pages8
JournalInternational Journal of Nephrology and Renovascular Disease
Volume10
DOIs
Publication statusPublished - Jun 22 2017

Fingerprint

Lipoid Nephrosis
Kidney
Podocytes
Membranous Glomerulonephritis
Organogenesis
Nephritis
Sclerosis
Immunosuppressive Agents
Proteinuria
Basement Membrane
Immunoglobulin A
Healthy Volunteers
Biomarkers
Drug Therapy
Therapeutics
Serum
Neoplasms
Proteins

Keywords

  • Biomarker
  • Minimal change nephrotic syndrome
  • Semaphorin3A

ASJC Scopus subject areas

  • Nephrology

Cite this

@article{5df53531fa5c486ea9a676628d656716,
title = "The level of urinary semaphorin3A is associated with disease activity in patients with minimal change nephrotic syndrome",
abstract = "Semaphorin3A is a secreted protein known to be involved in organogenesis, immune responses and cancer. In the kidney, semaphorin3A is expressed in the glomerular podocytes, distal tubules and collecting tubules, and believed to play a role in the regulation of the kidney development and function. We examined the serum and urinary semaphorin3A levels in 72 patients with renal disease and 5 healthy volunteers. The patients had been diagnosed with thin basement membrane disease (n=4), minimal change nephrotic syndrome (MCNS; n=22), IgA nephritis (n=21), membranous nephropathy (n=16) and focal segmental glomerular sclerosis (n=9). The level of urinary semaphorin3A in MCNS patients tended to be relatively high among all disease groups. We also investigated the urinary semaphorin3A level in 7 patients with MCNS from disease onset to remission during the drug therapy. MCNS patients in preremission states had higher urinary semaphorin3A levels than those in post-remission states receiving immunosuppressive therapies. These results suggested that the urinary semaphorin3A level correlates with the MCNS activity. Semaphorin3A has the potential as a biomarker for MCNS to clarify the reactivity for therapy and may be useful in examining other glomerular diseases with proteinuria as well.",
keywords = "Biomarker, Minimal change nephrotic syndrome, Semaphorin3A",
author = "Akiko Inoue-Torii and Shinji Kitamura and Jun Wada and Kenji Tsuji and Hirofumi Makino",
year = "2017",
month = "6",
day = "22",
doi = "10.2147/IJNRD.S132980",
language = "English",
volume = "10",
pages = "167--174",
journal = "International Journal of Nephrology and Renovascular Disease",
issn = "1178-7058",
publisher = "Dove Medical Press Limited",

}

TY - JOUR

T1 - The level of urinary semaphorin3A is associated with disease activity in patients with minimal change nephrotic syndrome

AU - Inoue-Torii, Akiko

AU - Kitamura, Shinji

AU - Wada, Jun

AU - Tsuji, Kenji

AU - Makino, Hirofumi

PY - 2017/6/22

Y1 - 2017/6/22

N2 - Semaphorin3A is a secreted protein known to be involved in organogenesis, immune responses and cancer. In the kidney, semaphorin3A is expressed in the glomerular podocytes, distal tubules and collecting tubules, and believed to play a role in the regulation of the kidney development and function. We examined the serum and urinary semaphorin3A levels in 72 patients with renal disease and 5 healthy volunteers. The patients had been diagnosed with thin basement membrane disease (n=4), minimal change nephrotic syndrome (MCNS; n=22), IgA nephritis (n=21), membranous nephropathy (n=16) and focal segmental glomerular sclerosis (n=9). The level of urinary semaphorin3A in MCNS patients tended to be relatively high among all disease groups. We also investigated the urinary semaphorin3A level in 7 patients with MCNS from disease onset to remission during the drug therapy. MCNS patients in preremission states had higher urinary semaphorin3A levels than those in post-remission states receiving immunosuppressive therapies. These results suggested that the urinary semaphorin3A level correlates with the MCNS activity. Semaphorin3A has the potential as a biomarker for MCNS to clarify the reactivity for therapy and may be useful in examining other glomerular diseases with proteinuria as well.

AB - Semaphorin3A is a secreted protein known to be involved in organogenesis, immune responses and cancer. In the kidney, semaphorin3A is expressed in the glomerular podocytes, distal tubules and collecting tubules, and believed to play a role in the regulation of the kidney development and function. We examined the serum and urinary semaphorin3A levels in 72 patients with renal disease and 5 healthy volunteers. The patients had been diagnosed with thin basement membrane disease (n=4), minimal change nephrotic syndrome (MCNS; n=22), IgA nephritis (n=21), membranous nephropathy (n=16) and focal segmental glomerular sclerosis (n=9). The level of urinary semaphorin3A in MCNS patients tended to be relatively high among all disease groups. We also investigated the urinary semaphorin3A level in 7 patients with MCNS from disease onset to remission during the drug therapy. MCNS patients in preremission states had higher urinary semaphorin3A levels than those in post-remission states receiving immunosuppressive therapies. These results suggested that the urinary semaphorin3A level correlates with the MCNS activity. Semaphorin3A has the potential as a biomarker for MCNS to clarify the reactivity for therapy and may be useful in examining other glomerular diseases with proteinuria as well.

KW - Biomarker

KW - Minimal change nephrotic syndrome

KW - Semaphorin3A

UR - http://www.scopus.com/inward/record.url?scp=85021329488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021329488&partnerID=8YFLogxK

U2 - 10.2147/IJNRD.S132980

DO - 10.2147/IJNRD.S132980

M3 - Article

AN - SCOPUS:85021329488

VL - 10

SP - 167

EP - 174

JO - International Journal of Nephrology and Renovascular Disease

JF - International Journal of Nephrology and Renovascular Disease

SN - 1178-7058

ER -